Evidence map›Paper›PMID 40599434›Full record

ReviewArchives of Razi Institute2024

A Concise Review of Major Challenges in the Vaccination, Diagnosis and Treatment of Novel Coronavirus Disease 2019.

N Bargahi, A Ghasemian, R Hoseinpoor, S Mahmoodi

Abstract readReview
In one paragraph

Review in Archives of Razi Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

N BargahiDepartment Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran, Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
A GhasemianNoncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
R HoseinpoorDepartment of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University, Tehran, Iran.
S MahmoodiDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid dissemination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in the 2019 coronavirus (COVID-19) pandemic on a global scale. An efficacious strategy to control the ongoing pandemic of the novel coronavirus disease (2019-nCoV) includes the rapid recognition of infected patients and the implementation of vaccination programs utilizing accurate and reliable methods. A variety of diagnostic techniques, including computed tomography (CT) scans, serological assays, and molecular methods, have been employed for the diagnosis of coronavirus disease 2019 (COVID-19). Furthermore, a variety of vaccines, antiviral drugs, and immunotherapies have been employed to combat the virus. This is of particular importance for patients diagnosed with SARS-CoV-2 infection who are at high risk of developing serious complications. The prognosis, diagnosis, vaccination, and treatment of COIVD-19 present a number of challenges, including variability in disease severity, the emergence of new variants, individual factors and immune responses, co-infections and complications, a lack of long-term data, psychological and social factors, the availability and accessibility of tests, the sensitivity and specificity of tests, variability in symptoms, mild or asymptomatic cases, a limited number of specific antiviral options, clinical heterogeneity, the lack of a universal treatment protocol, overburdened healthcare systems, the management of severe cases, long-term effects and post-COIVD-19 syndrome, vaccine hesitancy, global cooperation, and vaccine production capacity. This article presents an overview of the most recent advancements in the field of Coronavirus Disease 2019 (Covid-19), encompassing prognosis, diagnosis, vaccination, and therapy. It is of the utmost importance to consult reliable sources such as national health authorities and the World Health Organization (WHO) in order to obtain the latest information on the vaccination of individuals against the novel coronavirus, including details on eligibility, availability, and recommended protocols in any specific region. The range of available treatment options and strategies is subject to ongoing evolution. Healthcare professionals and researchers are assiduously striving to surmount the challenges inherent to therapy and to enhance the outcomes for those affected by SARS-CoV-2 infection. It is imperative that randomized clinical studies be conducted with the objective of identifying the most appropriate and proven treatment in order to reduce the prevalence of SARS-CoV-2 infection and to prevent the occurrence of future pandemics.

Indexed as

COVID-19COVID-19 VaccinesAntiviral AgentsCOVID-19 Drug TreatmentHumansSARS-CoV-2VaccinationAntiviral AgentsCOVID-19 VaccinesAntiviral TherapyCoronavirus Disease 2019DiagnosisPrognosisVaccination

Identifiers

PMID40599434
PMCPMC12207941

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.